Publications
Original scientific literature and review articles for the inhibition of transforming growth factor-beta 2 (TGF-β2) in malignant tumors:
2011
Akhurst R., Bogdahn U., Buijs J., Busse A., Connolly E., ten Dijke P., Goumans M.-J., Guise T., Hau P., Hilbig A., Hinck A., Ikushima H., Jachimczak P., Jaschinski F., Juarez P., Keilholz U., Lee W.-C., Ling L., Lonning S., Mannick J., McPherson J., van Meeteren L., Miyazono K., O'Connor-McCourt M., Oettle H., Rothhammer T., Schlaier J., Schlingensiepen K.-H., Schneider A., Seitz C.
Hot Topic: TGF-β As Target in Oncology
Current Pharmaceutical Biotechnology, Volume 12, Number 12fileadmin/data_antisense/pictures_videos_documents/Antisense_Pharma/Research_and_Development/Publications/2011_12_Current_Pharmaceutical_Biotechnology_Vol12_Content.pdf
2011
Schlingensiepen et al.
Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer
Cancer Science, doi: 10.1111/j.1349-7006.2011.01917.xhttp://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.2011.01917.x/abstract
2011
Bogdahn U. et al.
Neuro-Oncology 13, doi: 10.1093/neuonc/noq142http://www.antisense-pharma.com/fileadmin/data_antisense/PDF_Dokumente/Publikationen/Bogdahn_et_all_HGG_Neuro-Oncology_2010.pdf
2010
Schlingensiepen K.-H. et al.
Antisense Nucleic Acids in the Treatment of Malignant Tumors
In: Zeller WJ, zur Hausen H, editors. Oncology: Basics - diagnosis - therapy - developments. Landsberg / Lech: Ecomed, p. IV-20
2008
Schlingensiepen, K.-H. et. al.
Targeted Downregulation of TGF-beta_2 with AP 12009 in Tumor Therapy
From: Cancer Drug Discovery and Development: Transforming Growth Factor-beta in Cancer Therapy, Vol II: Cancer Treatment and Therapy, Chapter 38, pages 635-651, Humana Press Inc.
2008
Schlingensiepen, K.-H. et. al.
Antisense Therapeutics for Tumor Treatment - The TGF-beta_2 Inhibitor AP 12009 in Clinical Development against Malignant Tumors
From: Pancreatic Cancer, Part III: New Treatment Strategies and Outlook, Chapter 16, Pages 137-150, Springer
2007
Hau, P. and Jachimczak P. et. al.
Oligonucleotides 17: 201-212 http://www.liebertonline.com/doi/abs/10.1089/oli.2006.0053
2006
Schlingensiepen, K.-H. et. al.
Targeted tumor therapy with the TGF-beta2 antisense compound AP 12009
Cytokine Growth Factor Reviews 17: 129-139 http://www.sciencedirect.com/science/article/pii/S1359610105001061
2005
Schlingensiepen, R. et. al.
Oligonucleotides 15: 94-104http://www.liebertonline.com/doi/abs/10.1089/oli.2005.15.94
2005
Schlingensiepen, R. et. al.
Immunotherapy against malignant tumors with antisense AP 12009: Technology, Target, Therapy
Oncology Journal 07: 24-30http://www.journalonko.de/aktuellview.php?id=1173
Recommended further reading:
2012
Akhurst R. J. & Hata A.
Targeting the TGFβ signalling pathway in disease
Nature Reviews Drug Discovery 11: 790 - 811
2012
Massagué J.
TGFβ signalling in context
Nature Reviews Molecular Cell Biology 13: 616 - 630
2009
Padua D & Massague J.
Roles of TGF-β in metastasis
Cell Res.19 19: 89-102.
2010
Ikushima, H. & Miyazono, K.
TGFbeta signalling: a complex web in cancer progression
Nature Reviews Cancer 10: 415-424http://www.nature.com/nrc/journal/v10/n6/full/nrc2853.html
2008
Massagué J.
Cell. 2008 Jul 25;134(2):215-30. doi: 10.1016/j.cell.2008.07.001http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3512574/pdf/nihms412481.pdf
2008
Seoane J.
The TGF-β pathway as a therapeutic target in cancer
Clin Transl Oncol. 10: 14-9.
2006
Akhurst, R. J.
Large- and small-molecule inhibitors of transforming growth factor-beta signaling
Curr Op Invest Drugs 7: 513-521
Contact
Readers interested in our publications please contact us via:
publications@antisense-pharma.com
Akhurst R. J. & Hata A., 2012
Massagué J., 2008